Shanghai Yueyang Integrated Medicine Hospital
Shanghai, Shanghai Municipality, 200080, China
NCT Number: NCT06579976
Psoriasis (PsO) is a common chronic relapsing inflammatory disease, induced by a combination of genetic and environmental effects, which seriously affects the quality of life of patients.Psoriasis Area and Severity Index(PASI score ) ,as the most common method used by clinicians to assess the severity of psoriasis and the effectiveness of treatment, has the disadvantage of being subjective and superficial.We are therefore committed to establishing an objective, real-time, repeatable, non-invasive, microscopic assessment using high-frequency ultrasound. This study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Observational
Shanghai, Shanghai Municipality, 200080, China
High-frequency ultrasound (HFUS) with a center frequency of more than 10 MHz, and a resolution of 16-158 μm. The detailed detection items are epidermal thickness (unit mm), dermal thickness (unit mm), hypoechoic cord thickness between epidermis and dermis (unit mm), epidermal echo intensity, dermal echo intensity, clarity of the boundary between dermis and subcutaneous tissue detected by Grayscale ultrasound; blood flow signal (pcs) detected by Color Doppler imaging and Power doppler imaging. The 8 tests will be detected the skin lesions and 2cm beside skin lesions area.Based on the correlation between the 8 indexes and local PASI scores, we will establish a model for the evaluation of psoriasis by multimodal high-frequency ultrasound.This study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is an observational study, no intervention will be implemented.
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
epidermal thickness (unit mm) detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
dermal thickness (unit mm) detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
hypoechoic cord thickness between epidermis and dermis (unit mm) detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
epidermal echo intensity detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
dermal echo intensity detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
clarity of the boundary between dermis and subcutaneous tissue detected by Grayscale ultrasound
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
blood flow signal (pcs) detected by Color Doppler imaging
Time frame: Measurement of the patient's lesion and non-lesion areas were taken once 1 day
blood flow signal (pcs) detected by Power doppler imaging
Time frame: Measurement of the patient's lesion areas were taken once 1 day
Same scoring criteria as PASI scores without area factors.
Contact information is provided by the study sponsor or research team.
Xin Li, PhD
CONTACT
Yuanting Yu, bachelor
CONTACT
Shanghai Yueyang Integrated Medicine Hospital
Other
Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index:a Prospective Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07485764
Body Weight, Moderate-to-severe Plaque Psoriasis
Wuhan, Hubei, China
View Trial DetailsNCT07373847
Plaque Psoriasis
View Trial DetailsNCT07158268
Plaque Psoriasis
View Trial DetailsNCT07113756
Plaque Psoriasis
View Trial Details